- New technical article from gempex
- SWISO certification as proof of GACP compliance
THC hemp - a topic that is currently making its way into the industry with force.
In Switzerland in particular, it is not only the ongoing liberalization of medical cannabis that is contributing to this, but also the pilot trials with THC cannabis for non-medical, i.e. consumption purposes that began last year.
Numerous CBD hemp producers therefore want to take advantage of the opportunities, but often underestimate that it is not possible without the prerequisites of high-quality production of the plant starting materials - whether with regard to the regulating authorities or with regard to the important stakeholders.
This is because in order to be allowed to produce active pharmaceutical ingredients and hemp-based medicines, a pharmaceutical production license (establishment license) is required from the respective competent medicines control authority in both Germany and Switzerland.
This topic and a possible solution for the arising questions is dedicated to the new technical contribution of Dr. Ralf Prescher, Senior Consultant of gempex GmbH:
GACP for cannabis - implement professionally and with evidence.
An up-to-date view of the subject area will be presented, as well as the newly developed SWISO certification to demonstrate GACP compliance.
Focal points are:
- Medical cannabis and pilot testing for non-medical purposes - what to consider?
- GACP, GMP, GDP - The "Good Practice" - Experiences around audits and inspections
- GACP - a difficult field to work on so far
- SWISO certification - the label for proven GACP compliance
- GACP certification for cannabis - the way forward
The German language article is available for download at GMP-Knowledge.
Further information can be found on the topic page GMP for Cannabis .
For questions on this topic, Dr. Ralf Prescher is available at contact@gempex.com.